Arbutus Biopharma
ABUS
100 hedge funds and large institutions have $150M invested in Arbutus Biopharma in 2021 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 14 closing their positions.
77% more call options, than puts
Call options by funds: $13.7M | Put options by funds: $7.71M
71% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 14
71% more capital invested
Capital invested by funds: $87.6M → $150M (+$62.1M)
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
10% more funds holding
Funds holding: 91 → 100 (+9)
5.21% more ownership
Funds ownership: 29.99% → 35.2% (+5.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.4M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$2.98M |
| 3 |
Barclays
London,
United Kingdom
|
+$2.08M |
| 4 |
SG Americas Securities
New York
|
+$2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$4.15M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.1M |
| 3 |
CAC
Cowen and Company
New York
|
-$720K |
| 4 |
Two Sigma Advisers
New York
|
-$363K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$361K |
ABUS Hedge Fund Activity: Q3 2021 in Review
100 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2021, worth a combined $150M — up 71% from $87.6M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ABUS positions and 14 closed out — a net gain of 10 holders — while 31 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $3.4M. The largest seller was RTW Investments, cutting an estimated $4.15M.
- 100 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2021, up from 91 in Q2 2021.
- Funds reported $150M of Arbutus Biopharma stock for Q3 2021, up 71% quarter-over-quarter.
- 24 funds opened new Arbutus Biopharma positions in Q3 2021 and 14 closed out, a net change of +10 holders.
- The largest Arbutus Biopharma buyer in Q3 2021 was Millennium Management, an estimated $3.4M added.
- The largest Arbutus Biopharma seller in Q3 2021 was RTW Investments, an estimated $4.15M sold.
Based on aggregated 13F filings for Q3 2021.